Solutions to the comparator question in the absence of licensed comparators? A retrospective analysis of orphan drug and gene therapy reimbursement in EU5 markets

Previous PostReimbursement pathways and associated timelines in European gene therapies
Next PostA multinational assessment of direct and indirect costs from a survey of patients with idiopathic pulmonary fibrosis (IPF)